SLU-PP-332

SLU-PP-332

Names
Preferred IUPAC name 4-Hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide
Other names SLU-PP-332
Identifiers
CAS Number	303760-60-3
3D model (JSmol)	Interactive image
ChemSpider	673181
PubChem CID	5404083
InChI InChI=1S/C18H14N2O2/c21-17-9-7-15(8-10-17)18(22)20-19-12-13-5-6-14-3-1-2-4-16(14)11-13/h1-12,21H,(H,20,22)/b19-12- Key: RNZIMBFHRXYRLL-UNOMPAQXSA-N
SMILES C1=CC=C2C=C(C=CC2=C1)/C=N\NC(=O)C3=CC=C(C=C3)O
Properties
Chemical formula	C18H14N2O2
Molar mass	290.322 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

SLU-PP-332 is a compound which is a potent but non-selective estrogen-related receptor (ERR) agonist, acting most strongly at ERRα with an EC₅₀ of 98 nM. It was found to counteract metabolic syndrome in mice, suggesting a possible role for compounds from this class as medications for the treatment of obesity. ^{[1] [2] [3] [4] [5]}

Non-research use

Since SLU-PP-332 is still an Investigational New Drug, it has not yet been approved to be marketed for consumption by humans in the United States. However, it has been used experimentally by some in the bodybuilding and biohacking community. ^[6]

References

1. US 8680150,Zhi L, Hudson AR, Van Oeveren CA, Roach SL, Pickens JC, Shen Y, Cuervo C, Valdez LJ, Basinger J, Grant VH,"Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors.",issued 25 March 2014, assigned to Ligand Pharmaceuticals Inc. 
2. Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, et al. (April 2023). "Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity". ACS Chemical Biology. 18 (4): 756–771. doi:10.1021/acschembio.2c00720. PMC   11584170 . PMID   36988910. S2CID   257803892.
3. Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, et al. (September 2023). "A Synthetic ERR Agonist Alleviates Metabolic Syndrome". The Journal of Pharmacology and Experimental Therapeutics. 388 (2): 232–240. doi: 10.1124/jpet.123.001733 . PMC   10801787 . PMID   37739806. S2CID   262147173.
4. Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, Jones BA, et al. (September 2023). "Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney". The American Journal of Pathology. 193 (12): 1969–1987. doi:10.1016/j.ajpath.2023.07.008. PMC   10734281 . PMID   37717940. S2CID   262046570.
5. "Exercise-mimicking drug sheds weight, boosts muscle activity in mice". news.ufl.edu. Retrieved 2023-10-05.
6. "An Extensive Guide to SLU-PP-332: The New Exercise Mimetic". hqsarms.com. Retrieved 2026-01-01.